ArticleGeriatrics & gerontology international2025
Self-reported autonomic dysfunction could be a predictive marker for sarcopenia in Parkinson's disease.
Article in Geriatrics & gerontology international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Self-reported autonomic dysfunction could be a predictive marker for sarcopenia in Parkinson's disease.Geriatrics & gerontology international · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimAutonomic dysfunction and motor symptoms are prevalent in Parkinson's disease (PD). Motor symptoms influence sarcopenia; however, the association between sarcopenia and non-motor symptoms, particularly autonomic dysfunction, remains unclear. This study determined the effect of autonomic dysfunction on sarcopenia in patients with PD.
methodsConsecutive patients with PD (Hoehn and Yahr stages 1-3) without apparent dementia were screened. The Scales for Outcomes in Parkinson's Disease-Autonomic Questionnaire (SCOPA-AUT) was utilized to evaluate the severity of autonomic dysfunction. Sarcopenia was assessed using the 2019 Asian Diagnostic Criteria. This study examined whether the SCOPA-AUT and its domains were associated with sarcopenia and used receiver operating characteristic analysis to evaluate their predictive performance.
resultsOf the 124 patients (76 [61%] men; median age, 68 years) included, sarcopenia was identified in 31 (25%). Poisson regression analysis with a robust variance estimator showed that a higher SCOPA-AUT score is associated with sarcopenia (prevalence ratio 1.078, 95% CI 1.034-1.122, p < 0.001). Regarding SCOPA-AUT domains, higher scores for gastrointestinal functioning, urinary functioning and pupillomotor functioning were significantly associated with sarcopenia. Receiver operating characteristic analysis showed that the optimal cut-off value for SCOPA-AUT was 16 (area under the curve 0.730, 95% CI 0.615-0.844). For each SCOPA-AUT domain, a cut-off of 8 for gastrointestinal functioning (area under the curve 0.744, 95% CI 0.630-0.858) predicted sarcopenia more reliably than urinary and pupillomotor functioning.
conclusionsHigher SCOPA-AUT scores, particularly in the gastrointestinal function domain, might be an optimal predictive marker for sarcopenia in patients with PD. Geriatr Gerontol Int 2025; 25: 1074-1081.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.